JP Morgan Chase
SABS icon

JP Morgan Chase’s SAB Biotherapeutics SABS Stock Holding History

JP Morgan Chase’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$329 Sell
87
-1,903
-96% -$7.59K ﹤0.01% 7220
2025
Q4 		$7.44K Buy
1,990
+1,903
+2,187% +$6.26K ﹤0.01% 6736
2025
Q3 		$175 Hold
87
– – ﹤0.01% 7128
2025
Q2 		$152 Sell
87
-16
-16% -$26 ﹤0.01% 6804
2025
Q1 		$139 Sell
103
-2
-2% -$5 ﹤0.01% 6845
2024
Q4 		$401 Sell
105
-1
-0.9% -$3 ﹤0.01% 6828
2024
Q3 		$286 Hold
106
– – ﹤0.01% 6862
2024
Q2 		$329 Buy
106
+2
+2% +$7 ﹤0.01% 6729
2024
Q1 		$472 Buy
104
+9
+9% +$50 ﹤0.01% 6726
2023
Q4 		$654 Buy
95
+2
+2% +$17 ﹤0.01% 6893
2023
Q3 		$584 Buy
93
+5
+6% +$37 ﹤0.01% 6702
2023
Q2 		$731 Hold
88
– – ﹤0.01% 6501
2023
Q1 		$0 Hold
88
– – ﹤0.01% 7163
2022
Q4 		$1K Sell
88
-175
-67% -$1.6K ﹤0.01% 6436
2022
Q3 		$2K Buy
263
+82
+45% +$814 ﹤0.01% 6263
2022
Q2 		$3K Sell
181
-319
-64% -$6.7K ﹤0.01% 6247
2022
Q1 		$19K Buy
500
+117
+31% +$5.4K ﹤0.01% 6083
2021
Q4 		$30K Buy
+383
New +$35.9K ﹤0.01% 6113
2021
Q3 		– Sell
-2,692
Closed -$269K – 6745
2021
Q2 		$269K Hold
2,692
– – ﹤0.01% 5081
2021
Q1 		$264K Buy
+2,692
New +$269K ﹤0.01% 5033

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's SABS Position: Q1 2026 in Review

JP Morgan Chase reduced its SAB Biotherapeutics (SABS) stake by 96% in Q1 2026, selling an estimated $7.59K and leaving 87 shares worth $329. The position accounts for ﹤0.01% of the portfolio, ranked #7220.

JP Morgan Chase first reported a position in SABS in Q1 2021 and has held it in 20 quarters since. The position peaked at $269K in Q2 2021. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • JP Morgan Chase held 87 shares of SAB Biotherapeutics worth $329 as of Q1 2026.
  • JP Morgan Chase sold 1,903 SAB Biotherapeutics shares in Q1 2026, an estimated $7.59K.
  • SAB Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7220 holding.
  • JP Morgan Chase first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's SAB Biotherapeutics position peaked at $269K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.